References
- Jenner E. An inquiry into the causes and effects of the variolae vaccinae. London: Dawsons of Pall Mall; 1966.
- Goldsby RA, Kindt TJ, Osborne BA. Kuby immunology. 4th ed. New York (NY): W. H. Freeman and Company; 2000.
- UK Health Security Agency. Promotional material: vaccination timeline: historical vaccine development and introduction of vaccines in the UK [Internet]. London: UK Health Security Agency; 2013 [cited 2021 Mar 16]. Available from: https://www.gov.uk/government/publications/vaccination-timeline
- Chomiak TW, Luginbuhl RE, Helmboldt CF. Tissue culture and chicken embryo techniques for infectious laryngotracheitis virus studies. Avian Dis 1960;4:235-46. https://doi.org/10.2307/1587599
- Hilleman MR. Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. J Hum Virol 2000;3:63-76.
- Polio vaccines: WHO position paper: March, 2016. Wkly Epidemiol Rec 2016;91:145-68.
- Hughes JM. Emerging infectious diseases: a CDC perspective. Emerg Infect Dis 2001;7(3 Suppl):494-6. https://doi.org/10.3201/eid0707.017702
- Fuenmayor J, Godia F, Cervera L. Production of virus-like particles for vaccines. N Biotechnol 2017;39(Pt B):174-80. https://doi.org/10.1016/j.nbt.2017.07.010
- Ulmer JB, Valley U, Rappuoli R. Vaccine manufacturing: challenges and solutions. Nat Biotechnol 2006;24:1377-83. https://doi.org/10.1038/nbt1261
- Plotkin S. History of vaccination. Proc Natl Acad Sci USA 2014;111:12283-7. https://doi.org/10.1073/pnas.1400472111
- Abd El Fadeel MR, El-Dakhly AT, Allam AM, Farag TK, ElKholy AA. Preparation and efficacy of freeze-dried inactivated vaccine against bovine viral diarrhea virus genotypes 1 and 2, bovine herpes virus type 1.1, bovine parainfluenza-3 virus, and bovine respiratory syncytial virus. Clin Exp Vaccine Res 2020;9:119-25. https://doi.org/10.7774/cevr.2020.9.2.119
- Abdelrahman KA, Ghazy AA, Ata EB. Better understanding of important aspects associated with vaccines development for controlling viral diseases in animals. Int J Dairy Sci 2020;15:114-22. https://doi.org/10.3923/ijds.2020.114.122
- Choi KS. Newcastle disease virus vectored vaccines as bivalent or antigen delivery vaccines. Clin Exp Vaccine Res 2017;6:72-82. https://doi.org/10.7774/cevr.2017.6.2.72
- Yokoyama N, Maeda K, Mikami T. Recombinant viral vector vaccines for the veterinary use. J Vet Med Sci 1997;59:311-22. https://doi.org/10.1292/jvms.59.311
- Stobart CC, Moore ML. RNA virus reverse genetics and vaccine design. Viruses 2014;6:2531-50. https://doi.org/10.3390/v6072531
- Vrba SM, Kirk NM, Brisse ME, Liang Y, Ly H. Development and applications of viral vectored vaccines to combat zoonotic and emerging public health threats. Vaccines (Basel) 2020;8:680.
- Choi Y, Chang J. Viral vectors for vaccine applications. Clin Exp Vaccine Res 2013;2:97-105. https://doi.org/10.7774/cevr.2013.2.2.97
- Khattar SK, Collins PL, Samal SK. Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1. Vaccine 2010;28:3159-70. https://doi.org/10.1016/j.vaccine.2010.02.051
- Zhang M, Ge J, Wen Z, et al. Characterization of a recombinant Newcastle disease virus expressing the glycoprotein of bovine ephemeral fever virus. Arch Virol 2017;162:359-67. https://doi.org/10.1007/s00705-016-3078-2
- Kortekaas J, Dekker A, de Boer SM, et al. Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus. Vaccine 2010;28:2271-6. https://doi.org/10.1016/j.vaccine.2010.01.001
- Zhang GG, Chen XY, Qian P, Chen HC, Li XM. Immunogenicity of a recombinant Sendai virus expressing the capsid precursor polypeptide of foot-and-mouth disease virus. Res Vet Sci 2016;104:181-7. https://doi.org/10.1016/j.rvsc.2015.12.009
- Yang CD, Liao JT, Lai CY, et al. Induction of protective immunity in swine by recombinant bamboo mosaic virus expressing foot-and-mouth disease virus epitopes. BMC Biotechnol 2007;7:62.
- Ren ZJ, Tian CJ, Zhu QS, et al. Orally delivered foot-and-mouth disease virus capsid protomer vaccine displayed on T4 bacteriophage surface: 100% protection from potency challenge in mice. Vaccine 2008;26:1471-81. https://doi.org/10.1016/j.vaccine.2007.12.053
- Ren XG, Xue F, Zhu YM, et al. Construction of a recombinant BHV-1 expressing the VP1 gene of foot and mouth disease virus and its immunogenicity in a rabbit model. Biotechnol Lett 2009;31:1159-65. https://doi.org/10.1007/s10529-009-9988-2
- Kim SM, Park JH, Lee KN, et al. Robust protection against highly virulent foot-and-mouth disease virus in swine by combination treatment with recombinant adenoviruses expressing porcine alpha and gamma interferons and multiple small interfering RNAs. J Virol 2015;89:8267-79. https://doi.org/10.1128/JVI.00766-15
- Moraes MP, Mayr GA, Mason PW, Grubman MJ. Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Vaccine 2002;20:1631-9. https://doi.org/10.1016/S0264-410X(01)00483-2
- Kamel M, El-Sayed A, Castaneda Vazquez H. Foot-and-mouth disease vaccines: recent updates and future perspectives. Arch Virol 2019;164:1501-13. https://doi.org/10.1007/s00705-019-04216-x
- Comas-Garcia M, Colunga-Saucedo M, Rosales-Mendoza S. The role of virus-like particles in medical biotechnology. Mol Pharm 2020;17:4407-20. https://doi.org/10.1021/acs.molpharmaceut.0c00828
- Caldeira JC, Perrine M, Pericle F, Cavallo F. Virus-like particles as an immunogenic platform for cancer vaccines. Viruses 2020;12:488.
- Kundig TM, Klimek L, Schendzielorz P, Renner WA, Senti G, Bachmann MF. Is the allergen really needed in allergy immunotherapy? Curr Treat Options Allergy 2015;2:72-82. https://doi.org/10.1007/s40521-014-0038-5
- Zeltins A. Construction and characterization of virus-like particles: a review. Mol Biotechnol 2013;53:92-107. https://doi.org/10.1007/s12033-012-9598-4
- Zhao Q, Chen W, Chen Y, Zhang L, Zhang J, Zhang Z. Self-assembled virus-like particles from rotavirus structural protein VP6 for targeted drug delivery. Bioconjug Chem 2011;22:346-52. https://doi.org/10.1021/bc1002532
- Vicente T, Roldao A, Peixoto C, Carrondo MJ, Alves PM. Large-scale production and purification of VLP-based vaccines. J Invertebr Pathol 2011;107 Suppl:S42-8. https://doi.org/10.1016/j.jip.2011.05.004
- Kato T, Deo VK, Park EY. Functional virus-like particles production using silkworm and their application in life science. J Biotechnol Biomaterial 2012;S9:001.
- Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. Methods 2006;40:60-5. https://doi.org/10.1016/j.ymeth.2006.07.018
- Hervas-Stubbs S, Rueda P, Lopez L, Leclerc C. Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN. J Immunol 2007;178:2361-9. https://doi.org/10.4049/jimmunol.178.4.2361
- Mena JA, Kamen AA. Insect cell technology is a versatile and robust vaccine manufacturing platform. Expert Rev Vaccines 2011;10:1063-81. https://doi.org/10.1586/erv.11.24
- Naslund J, Lagerqvist N, Habjan M, et al. Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus. Virology 2009;385:409-15. https://doi.org/10.1016/j.virol.2008.12.012
- Lewis SA, Morgan DO, Grubman MJ. Expression, processing, and assembly of foot-and-mouth disease virus capsid structures in heterologous systems: induction of a neutralizing antibody response in guinea pigs. J Virol 1991;65:6572-80. https://doi.org/10.1128/jvi.65.12.6572-6580.1991
- Abrams CC, King AM, Belsham GJ. Assembly of foot-and-mouth disease virus empty capsids synthesized by a vaccinia virus expression system. J Gen Virol 1995;76(Pt 12):3089-98. https://doi.org/10.1099/0022-1317-76-12-3089
- Cao Y, Lu Z, Sun J, et al. Synthesis of empty capsid-like particles of Asia I foot-and-mouth disease virus in insect cells and their immunogenicity in guinea pigs. Vet Microbiol 2009;137:10-7. https://doi.org/10.1016/j.vetmic.2008.12.007
- Maclachlan NJ, Drew CP, Darpel KE, Worwa G. The pathology and pathogenesis of bluetongue. J Comp Pathol 2009;141:1-16. https://doi.org/10.1016/j.jcpa.2009.04.003
- Niedbalski W. Bluetongue vaccines in Europe. Pol J Vet Sci 2011;14:299-304. https://doi.org/10.2478/v10181-011-0048-1
- Stewart M, Dovas CI, Chatzinasiou E, et al. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection. Vaccine 2012;30:2131-9. https://doi.org/10.1016/j.vaccine.2012.01.042
- Blakney AK, Ip S, Geall AJ. An update on self-amplifying mRNA vaccine development. Vaccines (Basel) 2021;9:97.
- World Health Organization. WHO coronavirus disease (COVID-19) dashboard [Internet]. Geneva: World Health Organization; 2021 [cited 2021 Mar 16]. Available from: https://covid19.who.int/region/emro/country/eg
- Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther 2021;28:117-29. https://doi.org/10.1038/s41434-020-00204-y
- Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines: a new era in vaccinology. Nat Rev Drug Discov 2018;17:261-79. https://doi.org/10.1038/nrd.2017.243
- Case JB, Winkler ES, Errico JM, Diamond MS. On the road to ending the COVID-19 pandemic: are we there yet? Virology 2021;557:70-85. https://doi.org/10.1016/j.virol.2021.02.003
- Petsch B, Schnee M, Vogel AB, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 2012;30:1210-6. https://doi.org/10.1038/nbt.2436
- Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol 2020;92:418-23. https://doi.org/10.1002/jmv.25681
- Nakagawa S, Miyazawa T. Genome evolution of SARS-CoV-2 and its virological characteristics. Inflamm Regen 2020;40:17.
- Suthar MS, Zimmerman MG, Kauffman RC, et al. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep Med 2020;1:100040.
- Brunning A. What are the COVID-19 RNA vaccines and how do they work? [Internet]. London: Royal Society of Chemistry; 2020 [cited 2021 Mar 24]. Available from: https://www.compoundchem.com/2020/12/02/rna-vaccines/
- Dong Y, Dai T, Wei Y, Zhang L, Zheng M, Zhou F. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther 2020;5:237.
- El-Rhman MM, Abo El-Hassan DG, Awad WS, Salem SA. Serological evaluation for the current epidemic situation of foot and mouth disease among cattle and buffaloes in Egypt. Vet World 2020;13:1-9. https://doi.org/10.14202/vetworld.2020.1-9
- El Nahas AF, Salem SA. Meta-analysis of genetic diversity of the VP1 gene among the circulating O, A, and SAT2 serotypes and vaccine strains of FMD virus in Egypt. J Vet Res 2020;64:487-93. https://doi.org/10.2478/jvetres-2020-0069
- Lubroth J, Grubman MJ, Burrage TG, Newman JF, Brown F. Absence of protein 2C from clarified foot-and-mouth disease virus vaccines provides the basis for distinguishing convalescent from vaccinated animals. Vaccine 1996;14:419-27. https://doi.org/10.1016/0264-410X(95)00172-W
- Barnett PV, Geale DW, Clarke G, Davis J, Kasari TR. A review of OIE country status recovery using vaccinate-to-live versus vaccinate-to-die foot-and-mouth disease response policies I: benefits of higher potency vaccines and associated NSP DIVA test systems in post-outbreak surveillance. Transbound Emerg Dis 2015;62:367-87. https://doi.org/10.1111/tbed.12166
- Taylor G, Bruce C, Barbet AF, Wyld SG, Thomas LH. DNA vaccination against respiratory syncytial virus in young calves. Vaccine 2005;23:1242-50. https://doi.org/10.1016/j.vaccine.2004.09.005
- Blodorn K, Hagglund S, Fix J, et al. Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies. PLoS One 2014;9:e100392.
- Boone JD, Balasuriya UB, Karaca K, et al. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine 2007;25:672-8. https://doi.org/10.1016/j.vaccine.2006.08.025
- Perrin A, Albina E, Breard E, et al. Recombinant capripox-viruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants. Vaccine 2007;25:6774-83. https://doi.org/10.1016/j.vaccine.2007.06.052
- Anderson J, Hagglund S, Breard E, et al. Evaluation of the immunogenicity of an experimental subunit vaccine that allows differentiation between infected and vaccinated animals against bluetongue virus serotype 8 in cattle. Clin Vaccine Immunol 2013;20:1115-22. https://doi.org/10.1128/CVI.00229-13
- Anderson J, Hagglund S, Breard E, et al. Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle. Vaccine 2014;32:6614-21. https://doi.org/10.1016/j.vaccine.2014.09.066
- Beer M, Konig P, Schielke G, Trapp S. Diagnostic markers in the prevention of bovine herpesvirus type 1: possibilities and limitations. Berl Munch Tierarztl Wochenschr 2003;116:183-91.
- Chowdhury SI, Pannhorst K, Sangewar N, et al. BoHV-1-vectored BVDV-2 subunit vaccine induces BVDV cross-reactive cellular immune responses and protects against BVDV-2 challenge. Vaccines (Basel) 2021;9:46.
- Troncarelli MZ, Brandao HM, Gern J, Guimaraes AS, Langoni H. Nanotechnology and antimicrobials in veterinary medicine. Formatex 2013;13:543-56.
- Rizzo LY, Theek B, Storm G, Kiessling F, Lammers T. Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. Curr Opin Biotechnol 2013;24:1159-66. https://doi.org/10.1016/j.copbio.2013.02.020
- Wagner DA, Kelly SM, Petersen AC, et al. Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague. Acta Biomater 2019;100:326-37. https://doi.org/10.1016/j.actbio.2019.10.016
- Bhardwaj P, Bhatia E, Sharma S, Ahamad N, Banerjee R. Advancements in prophylactic and therapeutic nanovaccines. Acta Biomater 2020;108:1-21. https://doi.org/10.1016/j.actbio.2020.03.020
- Wagner-Muniz DA, Haughney SL, Kelly SM, Wannemuehler MJ, Narasimhan B. Room temperature stable PspA-based nanovaccine induces protective immunity. Front Immunol 2018;9:325.
- McGill JL, Kelly SM, Kumar P, et al. Efficacy of mucosal polyanhydride nanovaccine against respiratory syncytial virus infection in the neonatal calf. Sci Rep 2018;8:3021.
- Chenthamara D, Subramaniam S, Ramakrishnan SG, et al. Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res 2019;23:20.
- Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010;10:787-96. https://doi.org/10.1038/nri2868
- Maina TW, Grego EA, Boggiatto PM, Sacco RE, Narasimhan B, McGill JL. Applications of nanovaccines for disease prevention in cattle. Front Bioeng Biotechnol 2020;8:608050.
- Kim E, Lim EK, Park G, et al. Advanced nanomaterials for preparedness against (re-)emerging viral diseases. Adv Mater 2021;33:e2005927.
- Pan L, Zhang Z, Lv J, et al. Induction of mucosal immune responses and protection of cattle against direct-contact challenge by intranasal delivery with foot-and-mouth disease virus antigen mediated by nanoparticles. Int J Nanomedicine 2014;9:5603-18. https://doi.org/10.2147/IJN.S72318
- Mahony D, Cavallaro AS, Mody KT, et al. In vivo delivery of bovine viral diahorrea virus, E2 protein using hollow mesoporous silica nanoparticles. Nanoscale 2014;6:6617-26. https://doi.org/10.1039/C4NR01202J
- O'Connor AM, Hu D, Totton SC, et al. A systematic review and network meta-analysis of bacterial and viral vaccines, administered at or near arrival at the feedlot, for control of bovine respiratory disease in beef cattle. Anim Health Res Rev 2019;20:143-62. https://doi.org/10.1017/S1466252319000288
- Riffault S, Meyer G, Deplanche M, et al. A new subunit vaccine based on nucleoprotein nanoparticles confers partial clinical and virological protection in calves against bovine respiratory syncytial virus. Vaccine 2010;28:3722-34. https://doi.org/10.1016/j.vaccine.2010.03.008
- Riffault S, Hagglund S, Guzman E, et al. A single shot prefusion-stabilized bovine RSV F vaccine is safe and effective in newborn calves with maternally derived antibodies. Vaccines (Basel) 2020;8:231.
- Mansoor F, Earley B, Cassidy JP, et al. Intranasal delivery of nanoparticles encapsulating BPI3V proteins induces an early humoral immune response in mice. Res Vet Sci 2014;96:551-7. https://doi.org/10.1016/j.rvsc.2014.03.002
- Mansoor F, Earley B, Cassidy JP, Markey B, Doherty S, Welsh MD. Comparing the immune response to a novel intranasal nanoparticle PLGA vaccine and a commercial BPI3V vaccine in dairy calves. BMC Vet Res 2015;11:220.
- Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000;287:1816-20. https://doi.org/10.1126/science.287.5459.1816
- Mobini S, Chizari M, Mafakher L, Rismani E, Rismani E. Computational design of a novel VLP-based vaccine for hepatitis B virus. Front Immunol 2020;11:2074.
- Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 2010;33:530-41. https://doi.org/10.1016/j.immuni.2010.09.017